Oct 21 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it sued three medical spas and online vendors for selling products claiming to contain tirzepatide, the main ingredient in its ...

Eli Lilly (NYSE:LLY) is taking the unusual step ... marketed as Zepbound for weight loss and Mounjaro for type 2 diabetes, for medical records to examine potential safety concerns.

Stephanie Walker was diagnosed with metastatic breast cancer (MBC) nearly a decade ago — an experience she says transformed ...

Eli Lilly said on Monday it sued three medical spas and online vendors for selling products that claimed to contain tirzepatide, the main ingredient in its popular weight-loss medicine ...

Eli Lilly's (NYSE:LLY) weight-loss drug Zepbound is now reportedly covered by Medicare for the treatment of obstructive sleep ...

Jan 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the main ingredient in its popular ...

The CMS last month declined to include anti-obesity medications in its Medicare coverage for Part D, a move that Lilly says could interfere with patients getting the appropriate medical care.

It is tailored to patients being treated with Lilly's oncology drugs – which ... than 30 DiGAs that have approved for use by the BfArM medical regulator and are covered by the national GKV ...

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

Eli Lilly also filed lawsuits against compounding pharmacies and medical spas. Pharmaceutical company Eli Lilly warning in an open letter on Thursday about the dangers of fake and compounded ...